Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.38 |
| ▸ | CETP | P11597 | 5/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 3/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496365 | 0.92 | CETP (0.43) | CYSLTR2CYSLTR1CETPCRHR1LTC4S | |
| SCHEMBL4498143 | 0.87 | CETP (0.38) | CETPCRHR1S1PR1LTC4S | |
| SCHEMBL1587798 | 0.86 | CETP (0.39) | CETPCRHR1S1PR1PDK2LTC4S | |
| SCHEMBL22205111 | 0.83 | CETP (0.44) | CYSLTR2CYSLTR1CETPS1PR1LTC4S | |
| SCHEMBL4490321 | 0.82 | CETP (0.43) | CETPCRHR1LTC4S | |
| SCHEMBL1587422 | 0.80 | AR (0.37) | CETPCRHR1S1PR1LTC4SPPARG | |
| SCHEMBL4490780 | 0.80 | CETP (0.36) | CETPCRHR1 | |
| SCHEMBL4515207 | 0.79 | CETP (0.45) | CETPCRHR1LTC4S | |
| SCHEMBL5624201 | 0.79 | CETP (0.39) | CETPCRHR1 | |
| SCHEMBL4493484 | 0.78 | CETP (0.43) | CETPCRHR1S1PR1LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CYSLTR2 1167/4885CYSLTR1 1375/4885CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.